Dr. Laura Balmain, MD
What this data tells you about Dr. Balmain
Dr. Laura Balmain is an optician in Texarkana, TX, with 20 years in practice. Based on federal Medicare data, Dr. Balmain performed 11,132 Medicare services across 1,947 unique beneficiaries.
Between the years covered by Open Payments, Dr. Balmain received a total of $6,671 from 36 pharmaceutical and/or device companies across 470 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in optician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Balmain is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Vedolizumab infusion (Entyvio) | 6,300 | $17 | $50 |
| Chronic care management, additional 20 min/month | 1,887 | $37 | $92 |
| Chronic care management, first 20 min/month | 1,117 | $49 | $122 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 327 | $201 | $1,017 |
| Office visit, established patient (30-39 min) | 225 | $88 | $156 |
| Remote patient monitoring management, 20 min/month | 205 | $38 | $94 |
| Remote patient monitoring device, 30 days | 175 | $38 | $95 |
| Upper GI endoscopy with biopsy | 164 | $75 | $700 |
| Colonoscopy with biopsy | 137 | $89 | $804 |
| New patient office visit (45-59 min) | 130 | $110 | $261 |
| Office visit, established patient (20-29 min) | 74 | $60 | $120 |
| Hospital follow-up visit, moderate complexity | 69 | $62 | $109 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 55 | $170 | $1,559 |
| Detection test by nucleic acid for digestive tract pathogen, multiple types or subtypes, 6-11 targets | 44 | $258 | $657 |
| Diagnostic exam of large bowel using a flexible endoscope | 33 | $130 | $723 |
| Initial hospital admission, moderate complexity | 28 | $99 | $220 |
| Stool analysis for blood, by fecal hemoglobin determination by immunoassay | 25 | $16 | $56 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 24 | $178 | $723 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 23 | $80 | $547 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 22 | $47 | $172 |
| Initial hospital admission, high complexity | 21 | $136 | $306 |
| New patient office visit (30-44 min) | 20 | $65 | $184 |
| Measurement of liver stiffness | 14 | $8 | $125 |
| Insertion of guide wire with dilation of esophagus using a flexible endoscope | 13 | $109 | $750 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Balmain is a clinical cardiology specialist, with above-average Medicare volume (top 5% in TX), and low-engagement industry engagement, with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Balmain experienced with vedolizumab infusion (entyvio)?
Does Dr. Balmain receive payments from pharmaceutical companies?
How do Dr. Balmain's costs compare to other opticians in Texarkana?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology